Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons
1 |
Issuer |
Oxford BioMedica PLC |
2 |
Reason for notification |
Notification relates to DTR 3.1.2R |
3 |
Name of PDMR |
Martin Diggle |
4 |
Connected person |
Notification relates to following connected persons: Vulpes Testudo Fund |
5 |
Notification in respect of |
Notification in respect of holdings of persons in 4 above |
6 |
Description of shares |
Oxford BioMedica PLC ordinary shares of 1p each |
7 |
Name of registered shareholders and number of shares |
Vulpes Life Sciences Fund - 549,932,000 shares Vulpes Testudo Fund - 33,334,434 shares
|
8 |
Nature of transaction |
Disposal |
9 |
Number of shares acquired
|
N/A
|
10 |
Percentage of issued class acquired |
N/A
|
11 |
Shares disposed |
Vulpes Testudo Fund - 2,377,600
|
12 |
Percentage of issued class disposed |
Vulpes Testudo Fund - 0.08%
|
13/14 |
Price per share of transactions, and date |
Vulpes Testudo Fund Sold 2,377,600 shares @ £0.1009, 31 Aug 2017
|
15 |
Total holding following notification and total percentage holding following notification |
Vulpes Life Sciences Fund - 549,932,000 shares 17.7% Vulpes Testudo Fund - 30,956,834 shares 1.0% |
16 |
Date issuer informed |
05 Sept 2017 |
|
|
|
23 |
Any additional information |
None |
24 |
Contact name and telephone number |
S. Paynter, Chief Financial Officer Oxford BioMedica +44 (0)1865 783000 |